SCHEMBL2837606

SCHEMBL2837606

CCOC(=O)C1CCC=CCCCCN(C)C(=O)C2CC(Oc3nc(-c4ccc(OC)cc4)nc4c(C)c(OC)ccc34)CC2C(=O)N1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CTSS P25774 1/20 0.40
▸ CTSB P07858 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.31
▸ KDM4E B2RXH2 2/20 0.31
▸ THRB P10828 1/20 0.31
▸ MAPT P10636 2/20 0.30
▸ PIK3CD O00329 1/20 0.30
▸ USP2 O75604 1/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ HSP90AA1 P07900 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30
▸ CYP2C9 P11712 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30
▸ PDE4A P27815 1/20 0.30
▸ PDE4B Q07343 1/20 0.30
▸ PDE4C Q08493 1/20 0.30
▸ PDE4D Q08499 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3554588 0.95 CTSB (0.41) CTSSCTSBALDH1A1KDM4EMAPT
SCHEMBL2834384 0.92 CTSS (0.41) CTSSCTSBPDE4APDE4BPDE4C
SCHEMBL2839848 0.91 CTSS (0.40) CTSSCTSBALDH1A1MAPTTSHR
SCHEMBL2839736 0.88 CTSB (0.43) CTSSCTSBPDE4B
SCHEMBL2840101 0.85 CTSS (0.42) CTSSCTSB
SCHEMBL3554406 0.84 CTSS (0.43) CTSSCTSB
SCHEMBL2837887 0.83 CTSS (0.41) CTSSCTSBPDE4APDE4BPDE4C
SCHEMBL2837605 0.83 CTSS (0.52) CTSSCTSB
SCHEMBL2837610 0.83 CTSS (0.52) CTSSCTSB
SCHEMBL8251809 0.83 CTSS (0.52) CTSSCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7659245-B2 Macrocylic inhibitors of hepatitis C virus TIBOTEC PHARMACEUTICALS LTD (IE) 2010-02-09 — — US disclosed
EP-1912981-B1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS TIBOTEC PHARM LTD (IE) 2010-01-20 — — EP disclosed
US-20090118312-A1 Macrocylic Inhibitors of Hepatitis C Virus JANSSEN SCIENCES IRELAND UC (IE) 2009-05-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118312-A1 Macrocylic Inhibitors of Hepatitis C Virus CBR1, HAVCR2, AOC1 CTSS 624/4885CTSB 1213/4885ALDH1A1 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback